Tabassum Shagufta, Khakwani Mehnaz, Fayyaz Asiya, Taj Nadia
Dr. Shagufta Tabassum, FCPS, Department of Obstetrics & Gynaecology, Nishtar Medical University, Multan, Pakistan.
Dr. Mehnaz Khakwani, FCPS, Department of Obstetrics & Gynaecology, Nishtar Medical University, Multan, Pakistan.
Pak J Med Sci. 2022 Mar-Apr;38(4Part-II):878-882. doi: 10.12669/pjms.38.4.4635.
To observe the role of Mentzer index for differentiating iron deficiency anemia (IDA) and beta thalassemia trait (β TT) in pregnant women.
This cross-sectional study was conducted in Gynaecology & Obstetrics Department of Nishtar Medical University from October 2020 to March 2021. Non-consecutive sampling was applied. A total of 100 antenatal ladies with hemoglobin <11 gm/dl were included. Their complete blood counts were checked and Mentzer Index was calculated. Mentzer Index <13 points to diagnosis of β TT and >13 indicates IDA. The diagnoses were confirmed by serum iron studies and Hb electrophoresis. The sensitivity and specificity of Mentzer Index for both causes of microcytic hypochromic anemia was calculated.
Out of total 100 patients with microcytic hypochromic anemia, 87 had Mentzer Index >13 and IDA was confirmed in 86 out of 87 cases. Thirteen cases had Mentzer Index <13 and β TT was confirmed in eight of them. Thus, Mentzer Index has a sensitivity and specificity of 91% & 83% for IDA and 83% & 91% for β TT.
In this study, it was found that Mentzer Index can be used as a discriminatory test to differentiate between iron deficiency anemia and beta thalassemia trait. The high risk group can then be subjected to definitive diagnostic tests. This can result in better patient compliance and cost effectiveness.
观察门泽指数在鉴别孕妇缺铁性贫血(IDA)和β地中海贫血特征(β TT)中的作用。
本横断面研究于2020年10月至2021年3月在尼什塔尔医科大学妇产科进行。采用非连续抽样。共纳入100名血红蛋白<11 g/dl的产前女性。检查她们的全血细胞计数并计算门泽指数。门泽指数<13提示β TT诊断,>13提示IDA。通过血清铁研究和血红蛋白电泳确诊。计算门泽指数对小细胞低色素性贫血两种病因的敏感性和特异性。
在总共100例小细胞低色素性贫血患者中,87例门泽指数>13,其中86例确诊为IDA。13例门泽指数<13,其中8例确诊为β TT。因此,门泽指数对IDA的敏感性和特异性分别为91%和83%,对β TT的敏感性和特异性分别为83%和91%。
在本研究中,发现门泽指数可作为鉴别缺铁性贫血和β地中海贫血特征的鉴别试验。然后可对高危人群进行确定性诊断试验。这可提高患者依从性并具有成本效益。